Engagement of HLA-A*02 by the LIR-1-based inhibitory receptor blocks CAR activation, sparing HLA-A*02-positive cells. Cytotoxicity occurs only against CEA-positive, HLA-A*02-negative tumor cells via CAR T-cell killing (perforin/granzymes).